Bharat Biotech
Search results
Feb 27, 2024 · Get Biological E Ltd. live share price, historical charts, volume, market capitalisation, market performance, reports and other company details.
Company profile page for Biological E Ltd including stock price, company news, executives, board members, and contact information
At Biological E. Limited, we nurture healthy living through products that help the treatment and prevention of diseases.
Biological E. Limited is a Non-govt company, incorporated on 10 Dec, 1953. It's a public unlisted company and is classified as'company limited by shares'. Company's authorized capital stands at Rs 500.0 lakhs and has 99.0% paid-up capital which is Rs 495.0 lakhs.
Biological E embarked specialise in low-cost vaccines manufacturing. The company started manufacturing its flagship vaccine product, Pentavalent (DTP Hib HepB) in 2008. [5] Biological E is a major supplier of vaccines to international development and aid organisations such as WHO, UNICEF, BMGF. [5]
Jul 30, 2023 · Indian vaccine producer Biological E is in discussions with global private equity (PE) investors General Atlantic, and TA Associates, among others, to raise up to $250 million by selling a...
Jul 9, 2024 · The price of financial report of BIOLOGICAL E. LIMITED prepared by Tofler is INR 799. It is an easy-to-read PDF report on the company that includes five year financial information, ratio analysis, management, group structure, shareholding pattern and more.
Dec 28, 2022 · Synopsis. According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin.
biological e ltd. - Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and information in the form of graphs, charts, expert advice, and more to stay...
The ratings upgrade considers the robust revenue growth of Biological E. Limited (BEL/the company) in FY2022 with healthy margins, and the expected uptick in the vaccine and pharmaceutical segments, going forward.
